The prospect of a subcutaneous version of Bristol Myers Squibb’s (NYSE: BMY) immuno-oncology blockbuster Opdivo (nivolumab) has moved closer.
This comes with the news that the US Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) for this formulation of Opdivo - co-formulated with Halozyme Therapeutics’ (Nasdaq: HALO) proprietary recombinant human hyaluronidase (rHuPH20).
"An injection administered in three-to-five minutes rather than a 30-to-60-minute infusion"The agency has accepted the filing, which is based on Phase III data, across all previously-approved adult, solid tumor indications as monotherapy, monotherapy maintenance following completion of Opdivo plus Yervoy (ipilimumab) combinations, or in combination with chemotherapy or cabozantinib.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze